Tag: Triple agonist

In a phase 2 clinical trial, adults with obesity taking the highest dose of retatrutide lost an average of 24.2% of their body weight over 48 weeks. Beyond the impressive numbers, understanding how you feel on retatrutide involves a complex mix of metabolic changes, side effect management, and psychological shifts that quiet the internal "food noise".

Based on phase 2 clinical trials, the investigational drug retatrutide led to an average weight loss of up to 24.2% over 48 weeks in adults with obesity. So, what does retatrutide do? It offers a novel, multi-pronged approach to weight and metabolic health management by activating three distinct hormone pathways.

Retatrutide is a novel triple-agonist peptide under development for obesity and diabetes. So, **what is in retatrutide?** Its unique composition activates three key metabolic receptors, offering powerful weight loss and glucose control that surpasses earlier medications.